These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 1379921)

  • 21. Efficacy of once-a-day terazosin in benign prostatic hyperplasia: a randomized, double-blind placebo-controlled clinical trial.
    Fabricius PG; Weizert P; Dunzendorfer U; Hannaford JM; Maurath C
    Prostate Suppl; 1990; 3():85-93. PubMed ID: 1689173
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Use of terazosin and alfuzosin in the treatment of benign prostatic hypertrophy (BPH): our experience].
    Larosa M; Ferretti S; Salsi P; Simonazzi M
    Acta Biomed Ateneo Parmense; 1994; 65(1-2):23-8. PubMed ID: 7528458
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of prazosin, terazosin and tamsulosin in the treatment of symptomatic benign prostatic hyperplasia: a short-term open, randomized multicenter study. BPH Medical Therapy Study Group. Benign prostatic hyperplasia.
    Tsujii T
    Int J Urol; 2000 Jun; 7(6):199-205. PubMed ID: 10843450
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [A multicenter, fixed-flexible dose study of terazosin hydrochloride in the treatment of symptomatic benign prostatic hypertrophy].
    Park YC; Nishioka T; Arai Y; Tomoyoshi T; Kurita T; Hayashida H; Nagai N; Inoue H; Kataoka K; Kitagawa Y
    Hinyokika Kiyo; 1992 Jul; 38(7):857-68. PubMed ID: 1381869
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of terazosin and finasteride in symptomatic benign prostatic hyperplasia: A comparative study.
    Anwarul Islam AK; Kashem MA; Shameem IA; Kibria SA
    Bangladesh Med Res Counc Bull; 2005 Aug; 31(2):54-61. PubMed ID: 16967810
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [A randomized comparative study assessing once versus twice a day treatment of benign prostatic hyperplasia with terazosin].
    Suzuki H; Ohnishi T; Ikemoto I; Ohishi Y; Suzuki Y; Yamazaki H
    Hinyokika Kiyo; 2001 Feb; 47(2):77-81. PubMed ID: 11280890
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Terazosin. A pharmacoeconomic evaluation of its use in benign prostatic hyperplasia.
    Plosker GL; Goa KL
    Pharmacoeconomics; 1997 Feb; 11(2):184-97. PubMed ID: 10165827
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serial prostate-specific antigen measurements in men with clinically benign prostatic hyperplasia during a 12-month placebo-controlled study with terazosin. HYCAT Investigator Group. Hytrin Community Assessment Trial.
    Roehrborn CG; Oesterling JE; Olson PJ; Padley RJ
    Urology; 1997 Oct; 50(4):556-61. PubMed ID: 9338731
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeted transurethral microwave thermotherapy versus alpha-blockade in benign prostatic hyperplasia: outcomes at 18 months.
    Djavan B; Seitz C; Roehrborn CG; Remzi M; Fakhari M; Waldert M; Basharkhah A; Planz B; Harik M; Marberger M
    Urology; 2001 Jan; 57(1):66-70. PubMed ID: 11164146
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia.
    Lepor H; Auerbach S; Puras-Baez A; Narayan P; Soloway M; Lowe F; Moon T; Leifer G; Madsen P
    J Urol; 1992 Nov; 148(5):1467-74. PubMed ID: 1279214
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Terazosin in the treatment of benign prostatic hyperplasia: a multicentre, placebo-controlled trial.
    Lloyd SN; Buckley JF; Chilton CP; Ibrahim I; Kaisary AV; Kirk D
    Br J Urol; 1992 Nov; 70 Suppl 1():17-21. PubMed ID: 1281727
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Terazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia.
    Wilde MI; Fitton A; Sorkin EM
    Drugs Aging; 1993; 3(3):258-77. PubMed ID: 7686794
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Side effects of terazosin in the treatment of symptomatic benign prostatic hyperplasia.
    McKiernan JM; Lowe FC
    South Med J; 1997 May; 90(5):509-13. PubMed ID: 9160069
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Terazosin in the treatment of benign prostatic hypertrophy].
    Andres M; De Cobelli O; Carmignani L; Musci R; Kocjancic E; Panizzutti M; Rocco F
    Arch Ital Urol Androl; 1995 Feb; 67(1):37-9. PubMed ID: 7538386
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of terazosin in the treatment of benign prostatic hyperplasia.
    Elhilali MM; Ramsey EW; Barkin J; Casey RW; Boake RC; Beland G; Fradet Y; Trachtenberg J; Orovan WL; Schick E; Klotz LH
    Urology; 1996 Mar; 47(3):335-42. PubMed ID: 8633398
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The efficacy and safety of terazosin for the treatment of symptomatic BPH.
    Lepor H; Henry D; Laddu AR
    Prostate; 1991; 18(4):345-55. PubMed ID: 1711689
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Meta-analysis of randomized trials of terazosin in the treatment of benign prostatic hyperplasia.
    Boyle P; Robertson C; Manski R; Padley RJ; Roehrborn CG
    Urology; 2001 Nov; 58(5):717-22. PubMed ID: 11711348
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The treatment of benign prostatic hyperplasia with alpha blockers in men over the age of 80 years.
    Kaplan SA; Te AE; Ikeguchi E; Santarosa RP
    Br J Urol; 1997 Dec; 80(6):875-9. PubMed ID: 9439400
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The cost-effectiveness of terazosin and placebo in the treatment of moderate to severe benign prostatic hyperplasia.
    Hillman AL; Schwartz JS; Willian MK; Peskin E; Roehrborn CG; Oesterling JE; Mason MF; Maurath CJ; Deverka PA; Padley RJ
    Urology; 1996 Feb; 47(2):169-78. PubMed ID: 8607228
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Terazosin in the treatment of benign prostatic hyperplasia: the United States experience.
    Lepor H; Laddu A
    Br J Urol; 1992 Nov; 70 Suppl 1():2-9. PubMed ID: 1281728
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.